References

Antonelli, M. et al. 2022. “Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2.” The Lancet. Vol. 399, pp. 2263-2264.

Bowe, B., Xie, Y., Al-Aly, Z. 2023. Postacute sequelae of COVID-19 at 2 years. Nature Medicine; Vol. 29, pp. 2347–2357.

Bowe, B., Xie, Y., & Al-Aly, Z. 2022. “Acute and postacute sequelae associated with SARS-CoV-2 reinfection.” Nature Medicine.Vol. 28, pp. 2398–2405.

Cabot, J. and Bushnik, T. 2022, September 15. “Compliance with precautions to reduce the spread of COVID-19 in Canada.” Health Reports.

Davis, H. et al. 2023. “Long COVID: major findings, mechanisms and recommendations.” Nature Reviews Microbiology. Vol. 21, pp. 133-146.

Fernández-de-las-Peñas, C. et al. 2022. Long-COVID Symptoms in Individuals Infected with Different SARS-CoV-2 Variants of Concern: A Systematic Review of the Literature. Viruses 2022. Vol. 14, no. 2629.

Gupta, S. and Aitken, N. 2022, August 30. “COVID-19 mortality among racialized populations in Canada and its association with income.” StatCan COVID-19: Data to Insights for a Better Canada.

Health Canada. 2022, January 17. “Health Canada authorizes PAXLOVIDTM for patients with mild to moderate COVID-19 at high risk of developing serious disease.”

Health Canada. 2021, June 29. The state of virtual care in Canada as of wave three of the COVID-19 pandemic: An early diagnostic and policy recommendations.

Jennings, S., Corrin, T., and Waddell, L. 2023. “A systematic review of the evidence on the associations and safety of COVID-19 vaccination and post COVID-19 condition.” Epidemiology & Infection. Vol. 151, no. 145.

Mateu, L. et al. 2023. “Determinants of the onset and prognosis of the post-COVID-19 condition: a 2-year prospective observational cohort study.” The Lancet. Vol. 33, no. 100724.

Menni, C. et al. 2022. “Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study.” The Lancet. Vol. 399, pp. 1618-1624.

National Advisory Committee on Immunization (NACI). “Guidance on the use of COVID-19 vaccines in the fall of 2023.”

National Center for Health Statistics. “Long COVID Household Pulse Survey.”

Notarte, K.I. et al. 2022. “Age, Sex and Previous Comorbidities as Risk Factors Not Associated with SARS-CoV-2 Infection for Long COVID-19: A Systematic Review and Meta-Analysis.” Journal of Clinical Medicine. Vol 11, no. 7314.

Office for National Statistics (ONS). 2023, March 30. ONS website, statistical bulletin, “Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK.”

Public Health Agency of Canada. “COVID-19 epidemiology update: Current situation

Public Health Agency of Canada. 2023a. “Associations between Longer-term Symptoms after COVID-19 and Sociodemographics, Health Characteristics, Period of Infection, and Vaccination Status in Canadian Adults, January 2020 to August 2022.”

Public Health Agency of Canada. 2023b. “COVID-19: Prevention and risks.”

Public Health Agency of Canada. 2023c. “Seasonal Influenza Vaccination Coverage in Canada, 2021-2022.”

Public Health Agency of Canada. 2022a. “Are there clinically significant interactions between COVID-19 vaccination and post-COVID-19 condition (long COVID)?” CCDR. Vol. 48, no. 4.

Public Health Agency of Canada. 2022b. “People who are at risk of more severe disease or outcomes from COVID-19.”

Razak, F. et al. 2022. Canada’s response to the initial 2 years of the COVID-19 pandemic: a comparison with peer countries. CMAJ. Vol. 194, no. 870-7.

Skowronski, D. et al. 2023. “Risk of hospital admission and death from first-ever SARS-CoV-2 infection by age group during the Delta and Omicron periods in British Columbia, Canada.” CMAJ. Vol. 195, pp. 1427-1439.

Statistics Canada. 2022. “Long-term symptoms in Canadian adults who tested positive for COVID-19 or suspected an infection, January 2020 to August 2022.” The Daily.

Statistics Canada. 2023. “Between April and August 2022, 98% of Canadians had antibodies against COVID-19 and 54% had antibodies from a previous infection.” The Daily.

Statistics Canada. 2023. “Canadians' awareness of when they have COVID-19, May to August 2022.” The Daily.

Taquet, M. et al. 2021. “Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19” PLOS Medicine. Vol. 18, no. 1003773.

Tsampasian, V. et al. 2023. “Risk factors associated with post−COVID-19 condition: a systematic review and meta-analysis.” JAMA Internal Medicine. Vol. 183, pp. 566-580.

Venkatesan, P. 2022. “Do vaccines protect from long COVID?” The Lancet News. Vol. 10, no. 3.

WHO. “Coronavirus disease (COVID-19) pandemic.”

WHO. 2023. “Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic.”

WHO. 2021. “A clinical case definition of post COVID-19 condition by Delphi consensus, 6 October 2021.”

Woldegiorgis, M. et al. 2023. “Long COVID in a highly vaccinated population infected during a SARS-CoV-2 Omicron wave—Australia, 2022.” medRxiv. Preprint.

Woodrow, M. et al. 2023. “Systematic Review of the Prevalence of Long COVID.” Open Forum Infectious Diseases 2023; Vol. 10, no.7.

Date modified: